Migraine Market Analysis —
The global migraine market is predicted to grow at a notable CAGR over the forecast period (2013-2022), as per the latest Market Research Future (MRFR) report. Migraine is a common neurological condition which can cause multiple symptoms. Debilitating, intense headaches characterize this condition. Symptoms include sensitivity to sound and light, tingling or numbness, difficulty speaking, vomiting, and nausea. Often migraines run in families and affect every age.
Migraine is common in women compared to men, chiefly on account of the fluctuations that take place in the hormones. It is characterized into two types, migraine without aura or common migraines and migraine with aura called classical migraines. Usually, aura includes visual symptoms such as seeing flashes, shapes, or seeing lines. Often people may lose their vision for some time. Besides, they may also feel a tingling sensation in their legs and arms. The severity and symptoms can differ by attack, person, and over time.
Various factors are propelling the migraine market growth. These factors, as stated by the MRFR report, include rising adoption of novel drug classes, high unmet needs, the launch of CGRP (calcitonin gene-related peptide), increase in disease prevalence, and lifestyle changes. Additional factors pushing market growth include demand for hormonal medications, rising health expenditure, increasing female population, increasing prevalence of migraine, increasing cigarette consumption, and accelerating economic growth.
On the contrary, side effects related to migraine drugs may hamper the migraine market growth over the forecast period.
Get Free Sample of This Report @ https://www.marketresearchfuture.com/sample_request/2381
Migraine Market Segmentation
The Market Research Future report provides a wide segmental analysis of the migraine market based on drug class, treatment types, and types.
Based on type, the migraine market is segmented into chronic and episodic.
Based on drugs, the migraine market is segmented into ergots, triptans, and others.
Based on treatment types, the migraine market is segmented into abortive and preventive.
Migraine Market Regional Analysis
Based on the region, the migraine market report covers the latest trends and growth opportunities across Europe, Asia Pacific (APAC), North America, and the Rest of the World (RoW). Of these, North America will spearhead the market over the forecast period. The US is the key contributor in this region with more than 37 million suffering from migraine in the US alone. Besides, the other factors contributing to the market growth in this region include the huge target population in the US, adoption of new therapeutics, and the launch of CGRP based therapies.
The migraine market in the Asia Pacific is likely to have a healthy growth over the forecast period. This is owing to a huge underserved population, growing disease awareness, low-cost production of drugs, and rising healthcare expenditure.
The migraine market in Europe is predicted to have significant growth in the market over the forecast period. This is on account of the rising prevalence of hormonal imbalance, changing lifestyles, and rising stress levels.
Migraine Market Key Players
Leading players profiled in the migraine market report include GlaxoSmithKline plc, AstraZeneca plc, OptiNose, Merck, Meda, Luitpold Pharmaceuticals, Kowa Pharmaceuticals America, Klaria, Johnson & Johnson, Pfizer, Inc., Eli Lilly and Company, Eisai Inc., Abbott Laboratories, Inc., Impax Laboratories, and Allergan, among others. Key players have acquired several strategies to strengthen their position and create a foothold in the market. These include partnerships, acquisitions, mergers, product innovation, and product launch, expansion, research, and development activities, among others.
August 2019: DW Healthcare Partners recently has acquired CEFALY Technology SPRL, the leading Belgian manufacturers of neuro-modulating medical devices used to prevent and treat migraines. The CEFALY device is applied externally on the forehead of the patient. It delivers electrical impulses to a vital component of the nervous system, the trigeminal nerve that is involved in almost every migraine. This is a one of a kind device that is CE mark certified, registered with the FDA, and with several years of active commercial usage. The company’s robust and strong clinical data has successfully established CEFALY as an immensely effective as well as a safe solution for preventing and alleviating acute migraine pain.
Table Of Contents
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5 GLOBAL MIGRAINE MARKET , BY TYPES
Get access to full summary @ https://www.marketresearchfuture.com/reports/migraine-market-2381
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Name: Akash Anand
Email: Send Email
Organization: Market Research Future
Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India
Release ID: 88927802